A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer.

Trial Profile

A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Perifosine (Primary) ; Capecitabine
  • Indications Colorectal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms X-PECT
  • Most Recent Events

    • 29 Nov 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2010-0257)
    • 30 Jun 2012 Trial design and results presented at the 14th World Congress on Gastrointestinal Cancer.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top